acyl-CoA synthetase medium chain family member 2AGenealiases: A-923A4.1 · ACSM2
Q-omics provides the consensus-scored ACSM2A profile across patient tissues and cancer cell-line models. ACSM2A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ACSM2A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ACSM2A RNA expression shows 6,891 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KICH, and STAD as cancer lineages where ACSM2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSM2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSM2A survival associations across molecular data types. ACSM2A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSM2A RNA expression–survival associations across cancer types. High ACSM2A expression shows favorable associations in BRCA, BLCA, LIHC, KIRP, OV and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ACSM2A RNA expression.
This table summarizes ACSM2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSM2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSM2A shows lower tumor expression in KICH, THCA, COAD, LUAD, BRCA and CHOL. The KICH box plot shows higher ACSM2A RNA expression in normal versus tumor tissue (log2 FC = −4.792, t-test p < 0.001).
This table shows molecular features associated with ACSM2A in patient tissues and cancer cell lines. In patient samples, ACSM2A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSM2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OVARY.
